Placeholder canvas

Top Biopharma Deal July 2021: Arvinas – Pfizer ARV-471 PROTAC Protein Degrader for ER+/HER2- Breast Cancer

Aug 1, 2021 | Deal of the Month, Partnership Deals

July 2021 Top Biopharma Deal Upfront
Arvinas development and commercialization deal with Pfizer for ARV-471

Highlighted Deal Financial Comps

Date Announced:

July 22, 2021

Total Deal Value:


Upfront Cash:


Upfront Equity:

$350M (3.5M new common, 30% prem.)

Option Payments:


Total Milestones:

$1,400M ($400M Reg. and $1B Sales)



Cost & Profit Split:


Deal Synopsis

The Asset:

Phase II ARV-471 oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader for the treatment of estrogen receptor (ER) positive or human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) locally advanced or metastatic breast cancer.

Deal Structure:

Development and Commercial License

Partnership Features:

Equal cost and profit split for development and commercialization.

Deal Details:

  • Arvinas granted Pfizer exclusive, worldwide rights to develop and commercialize ARV-471 for ER+/HER2- breast cancer.
  • Arvinas and Pfizer will split development and commercialization costs and profits equally.
  • Arvinas will receive $650M in upfront cash and Pfizer will receive approximately 3.5M newly issued shares of Arvinas common stock at a 30% premium valued at $350M, which represents an approx. 7% equity ownership stake by Pfizer. Additionally, Arnivas is eligible for up to $400M in approval milestones and up to $1B in commercial milestones.

Last Month:

Congrats to Arvinas and Pfizer for landing the DealForma July 2021 Top Biopharma Deal of the Month. The Deal of the Month for June 2021 was iTeos and GSK’s TIGIT deal with $625M up front for EOS-448. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.

We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting to schedule your personalized demo.


Licensing Deals


Funding Rounds




Company Profiles


Other Deals


Drug Sales Figures

All of this by stage, disease indication, modality, target...

More Research by DealForma

Biopharma Venture Investment Through Q3 2023

Biopharma Venture Investment Through Q3 2023

Biopharma venture investment totals rebounded in Q3 2023, nearing 2020 quarterly levels. The number of rounds, especially for seed and Series A, are still depressed as we are seeing investors re-investing in later rounds of portfolio companies rather than new...

Biopharma M&A Through Q3 2023

Biopharma M&A Through Q3 2023

This is a quick readout of biopharma M&A activity through Q3 2023 as we track the prominent deals for the year leading up to year-end. Among some of the largest in biopharma are Novo Nordisk's acquisition of Inversago Pharma offering shareholders up to $1.075...

Biopharma R&D Partnerships – Q3 2023 Review

Biopharma R&D Partnerships – Q3 2023 Review

Biotech, pharma, and medtech R&D partnerships in Q3 2023 settled to pre-2020 levels on total deal announced values but again on fewer deals. Major deal announcements in Q3 included Pfizer / Flagship Pioneering, Alnylam / Roche, Nanobiotix / Janssen, Orionis /...